eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Actavis UK Ltd

Whiddon Valley, Barnstaple, Devon, EX32 8NS, UK
Telephone: +44 (0)1271 311 200
Fax: +44 (0)1271 346 106
WWW: http://www.actavis.co.uk
Medical Information Direct Line: +44 (0)1271 311 257
Medical Information e-mail: medinfo@actavis.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 19/09/2008
SPC Cymalon


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Cymalon


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet of 6.76g of granules contain the following actives:

Citric Acid (anhydrous) EP1063.00mg
Sodium Citrate dihydrate EP2819.00mg
Sodium Carbonate EP130.00mg
Sodium Bicarbonate EP1200.00mg

Go to top of the page
3. PHARMACEUTICAL FORM

Granules for solution.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Cymalon is indicated for the relief of symptoms due to cystitis in adult females only.


Go to top of the page
4.2 Posology and method of administration

Route of administration: Oral

Adults One sachet to be taken in water, three times a day over 48 hours.

Children Cymalon is not recommended for children.


Go to top of the page
4.3 Contraindications

Cymalon should not be taken in cases of pregnancy, heart disease, high blood pressure, any form of kidney disease or whenever a restricted salt intake is indicated.


Go to top of the page
4.4 Special warnings and precautions for use

Patients should be advised against repeated use. If symptoms persist 48 hours after treatment is completed you are advised to consult your doctor. Do not exceed the stated dose. Keep out of the reach of children.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Sodium containing preparations should be avoided by patients on lithium because sodium is preferentially absorbed by the kidney resulting in increased lithium excretion and reduced plasma levels.

Urinary alkalinisers should not be used with hexamine because it is only effective in acid urine.

The effects of a number of drugs may be reduced or increased by the alkalinisination of the urine and reduction in gastric pH brought about by the active ingredients in the product.


Go to top of the page
4.6 Pregnancy and lactation

Do not use during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

Sodium bicarbonate may cause flatulence.

Mild diuresis may occur.


Go to top of the page
4.9 Overdose

Excessive administration of sodium citrate may cause gastrointestinal discomfort and diarrhoea. Excessive doses of sodium salts may lead to sodium overloading and hyperosmolality. Excessive administration of bicarbonate may lead to hypokalaemia and metabolic alkalosis, especially in patients with impaired renal function. Treatment is symptomatic and consists of appropriate correction of fluid and electrolyte balance.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Sodium Bicarbonate increases the alkali reserve of the plasma and increases excretion of urine, which is rendered less acidic. Sodium Citrate is used to make the urine alkaline in the treatment of urinary tract infections. Citric acid increases the secretion of urine and renders it less acidic. It is also used in the preparation of effervescent granules to aid effervescence.


Go to top of the page
5.2 Pharmacokinetic properties

Cymalon is administered in the form of a solution.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Castor Sugar EP

Saccharin Sodium BP

Flavour Lemon Natural (F309)


Go to top of the page
6.2 Incompatibilities

There are no known records of incompatibilities.


Go to top of the page
6.3 Shelf life

36 months


Go to top of the page
6.4 Special precautions for storage

Protect from moisture.


Go to top of the page
6.5 Nature and contents of container

Cymalon granules are packed into low density polythene, aluminium foil and paper (PPFP) laminate sachets, each containing 6.76g granules. These are further packed into cardboard cartons each containing 6 sachets.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Actavis Group PTC ehf

Reykjavíkurvegi 76-78

220 Hafnarfjordur

Iceland.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 30306/0066


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

22 July 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

Go to top of the page
11 DOSIMETRY

Go to top of the page
12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS


More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21182/SPC/